Jyong Biotech Ltd (MENS) Wheel Strategy

Running a MENS wheel strategy lets you generate consistent premium income on Jyong Biotech Ltd while setting your own entry and exit prices on the underlying. Jyong Biotech Ltd's wheel combines cash-secured puts and covered calls into a repeatable cycle: sell puts at strikes where you'd be happy to own MENS, and if assigned, sell calls at strikes where you'd be happy to sell. Use our scanner to find the best MENS wheel strategy setups in real time.

The wheel works best on liquid, high-quality names with stable fundamentals and active options markets — exactly the profile many large-cap leaders fit. The mechanics are simple: sell a cash-secured put on MENS, collect premium, and either keep the premium if it expires worthless or take assignment at a discount to current price. Once assigned, sell covered calls against the shares to keep collecting premium until they're called away. Choosing the right strikes, expirations, and IV environment is what separates a profitable MENS wheel from a losing one.

Jyong Biotech Ltd. is a Taiwan-based biotech firm focused on developing and commercializing plant-derived drugs targeting urinary system diseases. The company operates through its subsidiaries—Health Ever Bio-Tech, Genvace, and others—working on drug candidates like MCS‑2 (for BPH) currently in Phase III, PCP (for prostate cancer) in Phase II, and IC in pre-clinical stages

The difference between a wheel that compounds and one that bleeds comes down to strike selection, IV timing, and discipline on assignment. Our scanner handles the heavy lifting: it ranks every leg of the MENS wheel strategy by delta, premium yield, IV rank, and days to expiration, so you can deploy capital where the math works. Build your MENS wheel strategy on data, not gut feel — and let the options wheel do what it does best: pay you to wait.